Cala Health
Bioelectronic medicine for chronic disease
- 101-200 employees
- Healthcare
- B2B
- MedTech
- East San Mateo, San Mateo, CA
Jump to section
Company mission
To transform the standard of care for chronic disease with non-invasive wearable neuromodulation therapies.
Our take
Essential Tremor is the most prevalent movement disorder in the world, with up to 5% of the global population affected by it. And yet, there were previously only two treatments: ongoing prescription drugs, which have side effects of drowsiness and nausea; or invasive surgery, which is costly and has risk of serious side effects.
Cala have developed a pioneering non-invasive treatment, which uses electrical stimulation from wearable device (it looks like a simple wristwatch) that monitors personal tremor levels and adapts its treatment to suit each patient. It is a world-leader in its field, and has revolutionized treatment for the 7 to 10 million Americans suffering from Essential Tremor.
Funding is focussed on expanding patient access, as well research into how to use their technology to treat Parkinson’s disease and other ailments.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 5 rounds)
Dec 2024
$50m
LATE VC
Nov 2021
$77m
LATE VC
$198.3m
Total funding
This company has top investors
Leadership
Kate Rosenbluth
(CSO & Board Director)Formerly a Consultant at Genentech, Scientist in Residence at Brainlab and Lecturer at Stanford.